Gilead Gets CHMP Nod for New HIV Combo
Executive Summary
Gilead has received the green light in the EU for marketing its newest fixed-dose HIV treatment Odefsey but its cannibalization of predecessor product Complera will not reach levels expected in the US as generic versions of older HIV combos are set to arrive earlier in the EU.
You may also be interested in...
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey
Gilead Sciences Inc. on March 1 gained the FDA's approval to market Odefsey as a treatment for HIV-1 infection – the second so-called TAF-based regimen to win the agency's OK.